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Summary
 
We propose that a novel mechanism of hepatocyte apoptosis, involving a cooperative interac-
tion between CD40 and Fas, is involved in the hepatocyte loss of chronic liver allograft rejec-
tion. We detected increased hepatocyte expression of Fas, Fas ligand (FasL), and CD40 associ-
ated with dropout of centrilobular (acinar zone 3) hepatocytes in chronic allograft rejection.
 
Expression of CD40 ligand (CD40L) was also increased but was largely restricted to CD68
 
1
 
macrophages. A functional role for CD40 and Fas in hepatocyte apoptosis was demonstrated in
vitro using primary human hepatocytes and the HepG2 cell line in both of which apoptosis was
induced, not only by cross-linking Fas directly but also via CD40 activation. Our data suggest
that CD40 activation induces apoptosis via Fas because (a) ligation of CD40 upregulated hepa-
tocyte FasL expression, and (b) apoptosis induced via activation of CD40 was prevented by a
neutralizing monoclonal antibody to FasL. Thus, CD40 engagement triggers apoptosis of hu-
man hepatocytes and might amplify Fas-dependent hepatocyte apoptosis in chronic rejection
and other inflammatory liver diseases in which Fas-mediated apoptosis is involved.
Key words: CD40 activation • apoptosis • hepatocytes • allograft rejection
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hronic rejection affects up to 10% of patients after
liver transplantation and is the major indication for re-
transplantation (1, 2). It fails to respond to increased immu-
nosuppression and is defined histologically by a progressive
loss of intrahepatic bile ducts, an occlusive arteriopathy, and
severe cholestasis associated with dropout of centrilobular
hepatocytes in acinar zone 3 (2). The pathogenesis of hepa-
tocyte loss is unknown, although apoptosis of affected hepa-
tocytes has been reported (3, 4). In the present study, we
investigated the underlying mechanisms and propose that
hepatocyte apoptosis occurs in response to a cooperative
interaction between Fas (CD95/Apo-1) and CD40, two
members of the TNF receptor superfamily that have impor-
tant roles in regulating cell proliferation and death (5–8).
Ligation of cell membrane Fas triggers apoptosis in many
cell types, including hepatocytes (5, 9), and FasL expression
in tissue is therefore tightly regulated and largely restricted
to immune-privileged sites such as the testis and eye (10).
Fas is involved in regulating hepatocyte survival, and ad-
ministration of anti-Fas Ab causes panacinar hepatocyte
death and acute liver failure, which can be prevented by
transfecting hepatocytes with the survival gene bcl-2 (9,
11). Inhibition of Fas on hepatocytes prevents fulminant
hepatitis in murine models of hepatitis B, and Fas has also
been implicated in hepatocyte apoptosis in alcoholic liver
disease and Wilson’s disease (12–15).
CD40 is expressed on subsets of leukocytes, endothe-
lium, and some epithelial cell lines (7, 16). Its ligand,
CD40L (CD154), is expressed on activated T cells, den-
dritic cells, and some endothelial cells and can engage
CD40 as a membrane-bound or soluble ligand (16–18).
CD40–CD40L interactions provide critical costimulatory
signals for clonal T cell expansion and promote T cell–
dependent activation of B cells, CTLs, and macrophages (6,
7, 17, 19). Ligation of endothelial CD40 increases adhesion
molecule expression, suggesting a wider role in lymphocyte
recruitment (18). It has been shown recently that ligation
of CD40 on epithelial cell lines can inhibit growth (16, 20), 
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although little is known about the expression or function of
CD40/CD40L in the liver.
 
Materials and Methods
 
Liver Tissue.
 
Needle biopsies were obtained from 24 liver trans-
plant recipients of whom 6 had mild acute rejection (defined as a
portal infiltrate on day 7 protocol biopsies in the absence of bio-
chemical graft dysfunction); 6 had severe acute rejection defined his-
tologically (2) and associated with biochemical dysfunction. Six had
chronic rejection, defined by standard histological and biochemical
criteria (1, 2) and a failure to respond to at least two cycles of high-
dose corticosteroid. Six had stable graft function (normal liver func-
tion 
 
.
 
1 yr after transplant). Maintenance immunosuppression was
with corticosteroids, azathioprine, and either cyclosporin or tacroli-
mus. Acute rejection episodes were treated with three daily doses of
200 mg prednisolone or 1 g methylprednisolone. Surplus liver tissue
from donor organs was used as nondisease controls (
 
n
 
 5 
 
6). Tissue
was snap frozen in CRYO-M-BED mounting medium (Bright Sci-
entific Instruments Ltd.) and stored at 
 
2
 
70
 
8
 
C.
 
Immunohistochemistry.
 
Standard techniques were used to stain
acetone-fixed 4-
 
m
 
 cryostat tissue sections (21). Polyclonal rabbit
Abs specific for Fas or FasL (Santa Cruz Biotechnology, Inc.)
were used at 1:50 for 1 h at room temperature and detected using
1:100 alkaline phosphatase–labeled swine anti–rabbit Ab visual-
ized with Fast red (Dako). CD40 was detected with an IgG1
mAb (16) and CD40L with an IgG2a mAb (a gift from Dr. R.
Armitage, Immunex Corp.). Primary mAb was localized using an
ABC detection kit (Vectastain; Novacastra Labs). The primary
Ab was omitted in control sections.
 
 
 
Dual immunofluorescence
was used to characterize CD40L-bearing cells. CD40L was de-
tected with FITC-labeled goat anti–mouse IgG2a secondary Ab
at 1:50, and the cell type was determined by double staining for
fibroblasts (IgG1 mAb; Dianova Labs); B cells (IgG1 mAb CD22;
Dako), T cells (rabbit anti-CD3; Dako), NK cells (IgG1 mAb
CD56; Dako), macrophages (IgG1 mAb anti-CD68; Dako), and
endothelium (IgG1 mAb anti-CD31, clone NIH31.1; a gift from
S. Shaw, National Institutes of Health) were detected with 1:50
TRITC-labeled goat anti–rabbit Ig or goat anti–mouse IgG1
(EuroPath, Cornwall, UK). Sections were blocked with 10%
FCS before primary Ab. In control sections, the primary Ab was
replaced by nonimmune serum. Dual staining cells were detected
by confocal microscopy (21).
 
Histological Assessment.
 
Staining was assessed blindly by S.G.
Hubscher and S.C. Afford using a previously validated semiquantita-
tive scale where 
 
2 
 
denotes no staining relative to control; 
 
1
 
 weak,
equivocal positivity, and 
 
111
 
 maximum staining (21). The dis-
tribution of staining on liver cell types was recorded.
 
Hepatocyte Studies.
 
Hepatocytes were isolated from human
donor livers that were surplus to clinical requirements using col-
lagenase perfusion and Percoll density gradient centrifugation.
Immediately after isolation, cells were resuspended in Williams E
medium containing hydrocortisone, insulin, glutamine (22) and
allowed to adhere for 2 h. Medium was then replaced, and cells
rested for 24 h before stimulation for 24 h with TNF-
 
a
 
 (10 ng/
ml), IL-1 (100 U/ml), anti-Fas Ab (1:25), 1–5 
 
m
 
g/ml purified
soluble recombinant CD40L (a gift from Dr. R. Armitage), anti-
CD40 mAb (1:100), or both anti-CD40 and TNF-
 
a
 
. In some
experiments, 40 ng/ml mAb NOK-1 (PharMingen) was used to
neutralize FasL. Cells were harvested by trypsinization for 5 min
with 0.25% vol/vol bovine pancreatic trypsin neutralized by 10%
FCS. In control experiments (
 
n
 
 5 
 
9), untreated hepatocytes were
sampled at 2 h after plating and subsequently at 24-h time inter-
 
vals for up to 4 d, and viability was determined by trypan blue
dye exclusion. The HepG2 cell line also expresses CD40 (23),
and the effects of CD40 activation and FasL neutralization were
studied on HepG2 cells cultured in DMEM plus 10% FCS and 2
mM 
 
l
 
-glutamine.
 
Assessment of Apoptosis.
 
Apoptosis was quantified on hepatocyte
and HepG2 cytospins using morphological criteria (cell shrinkage,
chromatin condensation, Councilman bodies) and in situ DNA end
labeling (ISEL) for detection of fragmented DNA (3, 24).
 
Flow Cytometry.
 
Hepatocytes were assessed for Fas, FasL,
CD40, or CD40L expression using a Coulter XL flow cytometer
and the above Ab followed by 1:20 FITC-labeled rabbit anti–
mouse Ig or FITC goat anti–rabbit Ig (Dako). Controls were iso-
type-matched Ig or nonimmune serum (25).
 
Results
 
Expression of CD40, CD40L, Fas, and FasL in Human
Liver Allografts.
 
In normal liver there was no detectable
CD40, CD40L, or FasL expression and only very weak dif-
fuse expression of Fas in hepatocytes. Stable allografts or
those with mild rejection showed similar staining, with
very weak hepatocyte Fas expression and no detectable
FasL or CD40L. In mild rejection weak CD40 and moder-
ate CD40L staining was confined to the portal infiltrate,
whereas in severe rejection CD40 was also detected on vas-
cular and sinusoidal endothelium (hepatocytes and biliary
cells were largely negative) and strong CD40L staining was
seen on the portal infiltrate (Table I, and Fig. 1). In chronic
rejection CD40 stained strongly on centrilobular hepato-
cytes and sinusoidal endothelium, and both CD40 and
 
Table I.
 
Expression of CD40, CD40L, Fas, and FasL in
Liver Allografts
 
CD40 CD40L Fas FasL
Severe Acute Rejection
BD
 
12 11
 
VEC
 
11 2 11 11
 
SEC
 
111 2 11 11
 
HEPS
 
2 2 11 11
 
INF
 
111 111 111 111
 
Chronic Rejection
BD
 
12 11
 
VEC
 
22 22
 
SEC
 
111 2 111 111
 
HEPS
 
111 2 111 111
 
INF
 
111 111 11 111
 
CD40, Fas, and their respective ligands were increased (compared with
normal tissue or tissue from patients with mild rejection) during severe
acute and chronic rejection. Strong expression of CD40 in centrilobu-
lar hepatocytes was only seen in chronic rejection, and CD40L expres-
sion was confined to the inflammatory infiltrate. Surviving intrahepatic
bile ducts were weakly positive for CD40, Fas, and FasL during
rejection. BD, bile ducts; VEC, vascular endothelium; SEC, sinusoids;
HEPS, hepatocytes; INF, inflammatory cells. 
443
 
Afford et al. Brief Definitive Report
 
CD40L were detected on the portal inflammatory infil-
trate. In addition, centrilobular areas contained large num-
bers of CD40L
 
1
 
/CD68
 
1
 
 macrophages (Fig. 2). Fas staining
in mild acute rejection was weak and restricted to hepato-
cytes, whereas in severe acute rejection it was also detected
on vascular and sinusoidal endothelium and more strongly
on hepatocytes throughout the lobule. FasL was absent in
mild acute rejection but was detected on vascular and sinu-
soidal endothelium and hepatocytes in severe acute rejection
when the portal infiltrate was also strongly positive. In pa-
tients who had progressed to chronic rejection, Fas expres-
sion persisted on sinusoidal endothelium and hepatocytes,
with particularly intense staining associated with hepatocyte
loss in centrilobular regions. FasL was detected on endothe-
lium and on centrilobular hepatocytes (Table I, and Fig. 1).
 
Expression of Fas, FasL, CD40, and CD40L on Isolated
Hepatocytes.
 
In the absence of activation, cultured human
hepatocytes expressed Fas (64.5
 
 6 
 
3.7% positive), CD40
(33 
 
6 
 
6.8%), and low levels of FasL (7.9 
 
6 
 
2.6%) but not
CD40L (1.1 
 
6 
 
0.5%). Stimulation with TNF-
 
a
 
, IFN-
 
g
 
,
IL-1, TGF-
 
b
 
, or LPS or activation of CD40 did not
change levels of cell surface Fas or CD40 and failed to in-
duce CD40L (data not shown), whereas cell surface FasL
expression increased after treatment with IL-1, anti-CD40,
or anti-Fas. The largest increase in FasL was seen after
CD40 ligation (Fig. 3).
 
The Effect of Activation of Fas or CD40 on Hepatocyte Apop-
tosis.
 
The viability of the untreated hepatocytes at 2 h was
 
99.6 
 
6 
 
0.4% and remained high beyond the duration of the
experiment (viability at 4 d 98.1 
 
6 
 
0.6%). Activation of ei-
ther Fas or CD40 with cross-linking Ab induced hepatocyte
apoptosis, and similar results were seen using soluble CD40L
(Fig. 4). CD40-mediated apoptosis was prevented by addi-
tion of NOK-1, the neutralizing Ab to FasL. Comparable
results were obtained using the HepG2 cell line (Fig. 4).
Figure 1. CD40, CD40L, Fas, and FasL
are increased in severe acute and chronic re-
jection. (a) In severe acute rejection CD40
expression was strongest in inflammatory
cells (IC) and in sinusoids, which are also
shown in the higher magnification (inset).
(b) CD40L was confined to inflammatory
cells. In chronic rejection centrilobular
hepatocytes (also shown in the inset at
higher magnification) were strongly positive
for CD40 (c), and surrounding inflamma-
tory cells were CD40L1 (d). Hepatocyte
expression of Fas (e) and FasL (f) was con-
centrated in centrilobular areas in chronic
rejection. H, positive stained hepatocytes.
Figure 2. CD40L1 cells in chronic rejection are CD681 macrophages.
Dual staining was carried out using FITC-labeled anti-CD40L and TRITC-
labeled anti-CD68 in chronic rejection. High-magnification sections of
the centrilobular area are shown analyzed by confocal microscopy. Red,
CD402/CD681 cells; green, CD40L1/CD682 cells; yellow (marked with
arrows), CD40L/CD68 double-positive cells. 
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Discussion
 
In this study we show that Fas/FasL and CD40/CD40L
are increased in the human liver allograft during rejection,
and provide evidence that these pathways cooperate in me-
diating hepatocyte death in chronic allograft rejection. We
confirm the ability of Fas activation to induce apoptosis of
human hepatocytes in vitro (9, 11, 12) and in addition show
for the first time that engagement of hepatocyte CD40 by
Ab or soluble CD40L is an equally potent inducer of apop-
tosis. The ability of CD40 ligation to induce hepatocyte
death was surprising, given that the CD40 cytoplasmic tail
does not contain a conventional death domain, and sug-
gested to us that an indirect mechanism might be operating.
We propose that this mechanism involves activation of Fas
by autocrine or paracrine FasL because (a) CD40 ligation in-
duces hepatocyte FasL expression, thereby providing the
ligand to activate Fas on autologous or adjacent hepatocytes,
and (b) CD40-induced apoptosis was blocked by a neutraliz-
ing anti-FasL Ab. Thus CD40 engagement can trigger Fas-
dependent apoptosis of human hepatocytes and the HepG2
cell line, suggesting that this is an important mechanism for
apoptotic death in cells of hepatocyte lineage.
The Fas pathway has been implicated in hepatocyte apop-
tosis in several diseases (12–15). In normal human liver we
observed only weak Fas expression on hepatocytes and
no FasL. Findings were similar in biopsies from stable trans-
plants but not in those from patients with allograft rejection
in whom striking upregulation of both Fas and FasL was
observed. CD40 was not detected in normal liver, but in
chronic allograft rejection it was upregulated on hepatic en-
dothelium, bile ducts, and particularly on centrilobular hepa-
tocytes in areas of hepatocyte loss. That hepatocyte CD40
expression was only seen in chronic rejection whereas Fas
was detected in both acute and chronic rejection suggests
that the coexpression of Fas and CD40 might be a factor in
determining progression from acute to chronic rejection.
Fas and FasL expression was also detected on the portal
infiltrate in acute rejection, reflecting the presence of acti-
vated lymphocytes within the graft. Although increased Fas
expression by hepatocytes could increase their susceptibility
to cytolysis by FasL-bearing CTLs, hepatocyte damage is
not a conspicuous feature of acute rejection and our previ-
ous studies showed little hepatocyte apoptosis in acute re-
jection (3). Coexpression of CD40 and Fas on centrilobular
hepatocytes was only seen in chronic rejection, and it is
these patients who develop hepatocyte apoptosis. This sug-
gests that these molecules cooperate to cause target cell
damage and thus determine the severity of allograft rejec-
tion. The present study provides a molecular mechanism to
explain this. Isolated primary human hepatocytes expressed
both CD40 and Fas in culture, allowing us to determine
the consequences of engaging hepatocyte cell surface Fas
and CD40. The expression of CD40 and Fas on human
hepatocytes in culture is at odds with the apparent absence
of staining in normal tissue. This anomaly is probably due
to activation induced by the isolation and culture proce-
dures, because previous studies have shown CD40 upregu-
lation on cultured epithelial cell lines (16, 20).
Cross-linking of hepatocyte Fas in vitro induced a high
level of apoptosis, suggesting that FasL-bearing cells could
promote hepatocyte apoptosis in chronic rejection. How-
ever, we detected relatively few FasL
 
1
 
 lymphocytes in
chronic rejection despite many apoptotic hepatocytes,
which led us to look for an alternative source of FasL. Un-
der some circumstances hepatocytes express FasL which
can cause Fas-mediated suicide or fratricide (14, 15), and
we thought a similar mechanism could be involved in
chronic rejection where centrilobular hepatocytes coex-
press Fas and FasL. Moreover, activation of hepatocytes in
vitro with cross-linking Ab resulted in an increase in hepa-
tocyte cell surface FasL. IL-1 also upregulated cell surface
FasL (Fig. 3 a) and induced apoptosis in primary human
hepatocytes (data not shown), and this has been previously
reported in other types of epithelial cells (26). Centrilobular
hepatocytes in chronic rejection also stained strongly for
CD40, and cross-linking of CD40 caused hepatocyte apop-
tosis that was comparable to that seen with direct Fas acti-
vation (Fig. 4). Because the Fas pathway is known to be a
potent inducer of hepatocyte apoptosis (9, 11, 12), we in-
vestigated the consequences of CD40 ligation on FasL ex-
pression in isolated human hepatocytes.
Engagement of CD40 led to increased expression of cell
surface FasL and to induction of apoptosis that was compa-
rable to that induced by Fas cross-linking. Furthermore,
CD40-induced apoptosis could be prevented by a neutral-
izing Ab to FasL, providing evidence of a direct link be-
tween CD40 and Fas in the regulation of apoptosis. The
Figure 3. FasL expression is in-
creased on primary human hepato-
cytes in vitro after CD40 activa-
tion. Expression of FasL in resting
cells was low but increased signifi-
cantly after activation by IL-1,
anti-Fas, or anti-CD40. Data
shown are percentage of cells posi-
tive by flow cytometry (a). CD40
activation did not affect Fas expres-
sion. Histograms from a representa-
tive experiment for FasL (b) and
Fas (c) before (shaded) and after
CD40 activation are shown. 
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ability of hepatocytes to induce FasL-mediated apoptosis
after engagement of CD40 suggests that CD40 promotes
apoptosis via autocrine or fratricrine activation of Fas. It is
notable that CD40 and Fas expression on centrilobular
hepatocytes was seen in chronic rejection but not in severe
acute rejection where the cells expressed Fas but not
CD40. Hepatocyte apoptosis is not a conspicuous feature
of acute rejection, and it is possible that Fas expression
alone does not provide a potent enough signal.
Thus, CD40 may be a critical factor in the amplification
of hepatocyte apoptosis in chronic rejection, and we subse-
quently looked for a cellular source of CD40L. Hepato-
cytes did not express CD40L protein or mRNA in vitro
even after cytokine stimulation, and immunostaining of
hepatocytes in tissue sections was consistently negative.
However, CD40L was detected on CD68
 
1
 
 macrophages/
Kupffer cells in the centrilobular areas. In contrast very few
infiltrating CD3
 
1
 
 T cells expressed CD40L. Thus, CD40L/
CD68
 
1
 
 macrophages could provide the ligand for activa-
tion of hepatocyte CD40 in chronic rejection. This model,
in which continuing hepatocyte damage is promoted by
activated macrophages rather than by cytolytic T cells,
could explain why centrilobular hepatocyte dropout con-
tinues in chronic rejection in the absence of a marked lym-
phocytic infiltrate, and why chronic rejection often fails to
respond to antilymphocyte therapy (1).
In severe acute rejection CD40 was detected strongly on
graft endothelium, whereas it was not detected in patients
with mild self-limiting rejection, suggesting that CD40/
CD40L might also be involved in amplifying and maintain-
ing lymphocyte recruitment during graft rejection. In sup-
port of this, recent studies have shown that ligation of
CD40 on cultured endothelial cells results in increased ex-
pression of adhesion molecules, including vascular cell ad-
hesion molecule 1 (VCAM-1) and intercellular adhesion
molecule 1 (ICAM-1 [18]), that are expressed at high levels
on endothelium in graft rejection. Thus, the induction and
maintenance of these molecules might be a consequence of
CD40 ligation on graft endothelium (27, 28).
Until now, little was known about the expression and
function of CD40 in human liver. Our studies demonstrate a
novel mechanism by which CD40L-bearing cells can amplify
hepatocyte apoptosis through a Fas-dependent mechanism.
A similar mechanism will likely apply to other diseases in
which hepatocytes are destroyed by Fas activation, and in sup-
port of this we have recently detected CD40 on hepatocytes
in viral hepatitis and alcoholic liver disease (12–15; Afford,
S.C., P.L.
 
 
 
Shields, and D.H. Adams, unpublished observa-
tions). We thus propose that this model is a mechanism of
liver damage in a broad range of inflammatory liver diseases.
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Figure 4. CD40 activation triggers FasL-dependent hepatocyte and
HepG2 apoptosis. (a) Activation of CD40 with mAb induced apoptosis in
hepatocytes and HepG2 cells. Treatment of unstimulated cells with
NOK-1, a neutralizing Ab to FasL, alone had no effect, whereas NOK-1
inhibited apoptosis induced via CD40 activation. Results shown as per-
centage of cells positive by ISEL staining. White bars, results for primary
hepatocytes; hatched bars, results for HepG2 cells. (b and c) ISEL staining
of untreated hepatocytes or cells treated with 1 mg/ml soluble trimeric
CD40L, respectively, demonstrating that soluble CD40L also induced
hepatocyte apoptosis. 
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